Phlebotomy-only maintenance in PV

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-09-29 — Rusfertide Approval Expands Options and Improves Burdens in Polycythemia Vera: cross-connection with rusfertide: NCCN Category 1 placement positions rusfertide as a phlebotomy-sparing option across risk strata, directly altering the phlebotomy-only maintenance paradigm in PV. (novelty: 4)
• 2026-09-01 — FDA Approves Mimrylo (rusfertide) for Polycythemia Vera: cross-connection with rusfertide: Rusfertide’s FDA approval for erythrocytosis control in PV positions it as a mechanistically distinct alternative to phlebotomy-only maintenance. (novelty: 4)
• 2026-08-31 — FDA Approves First-of-its-Kind Drug for Polycythemia Vera (Rusfertide/Mimrylo): cross-connection with rusfertide: Rusfertide offers a phlebotomy-sparing physiologic alternative for PV patients inadequately controlled on existing therapies including phlebotomy alone. (novelty: 4)
• 2025-06-26 — Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.: Prospective trial data (trial-early) in low-risk PV requiring cytoreduction show ropeginterferon alfa-2b substantially cuts phlebotomy need with high CHR rates — further eroding phlebotomy-only maintenance as a sufficient strategy for low-risk PV patients who cross the cytoreduction threshold. (novelty: 3)
• 2026-08-01 — Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis.: PRISMA meta-analysis of 3 RCTs (n=522, meta-analysis): ropeginterferon alfa-2b is superior to phlebotomy alone for complete hematologic response, partial molecular response, and JAK2V617F allele-burden reduction — pooled quantitative evidence reinforcing the case against phlebotomy-only maintenance monotherapy in PV. (novelty: 3)
• 2026-07-22 — Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study.: Large US retrospective claims analysis (n=11,311, observational): despite phlebotomy ± cytoreduction as standard of care, most PV patients fail to sustain HCT <45%, and thromboembolic events, symptom burden, and post-TE costs remain high — quantifying real-world inadequacy of phlebotomy-anchored maintenance. (novelty: 3)
• 2026-07-17 — Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.: Cross-study meta-analysis reinforces phlebotomy independence as the key clinical outcome benchmark: ropeginterferon alfa-2b (both HIDAT and slow titration) delivers durable phlebotomy-free intervals in both low- and high-risk PV, with HIDAT achieving this endpoint faster. (novelty: 3)
• 2026-06-15 — A Study of Rusfertide in Japanese Adults With Polycythemia Vera: Japanese rusfertide PV trial uses phlebotomy need as a key efficacy endpoint, again positioning phlebotomy burden as the clinical benchmark hepcidin mimetics aim to displace. (novelty: 3)
• 2026-06-01 — A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera: Sapablursen PV trial uses phlebotomy frequency as a primary endpoint, framing phlebotomy burden as the clinical benchmark that novel hepcidin/iron-restrictive therapies aim to displace. (novelty: 4)
• 2026-04-08 — A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.: Review (citing Low-PV trial) reinforces inferiority of phlebotomy-only maintenance vs ropeginterferon alfa-2b in low-risk PV and argues against continued endorsement as monotherapy, advocating early rIFNα use across all PV risk groups. (novelty: 3)

Open questions

Related